Stockscreener 앱 받기
5.96
2.94%
0.17
Vir Biotechnology Inc 주식(VIR)의 최신 뉴스
Vir Biotechnology issues license to Norgine to market hepatitis D candidate - MSN
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Sell Signal: Will Vir Biotechnology Inc stock benefit from M A activityJuly 2025 Decliners & Expert Verified Movement Alerts - moha.gov.vn
What is HC Wainwright's Forecast for VIR FY2025 Earnings? - MarketBeat
Aug PreEarnings: Why Vir Biotechnology Inc stock remains resilientJuly 2025 Retail & Real-Time Volume Analysis Alerts - moha.gov.vn
Vir Biotechnology (NASDAQ:VIR) Stock Price Down 3.4%Here's What Happened - MarketBeat
VIR: HC Wainwright & Co. Reiterates 'Buy' Rating with $15 Price Target | VIR Stock News - GuruFocus
H.C. Wainwright reiterates Buy rating on Vir Biotechnology stock By Investing.com - Investing.com Canada
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Vir Biotechnology Inc. stock beat market expectations this quarterEarnings Risk Report & Stepwise Trade Signal Implementation - Улправда
EV Market: Can Vir Biotechnology Inc. stock resist market sell offsEarnings Recap Summary & Precise Buy Zone Tips - Улправда
Aug Swings: Will Vir Biotechnology Inc stock benefit from M A activityOptions Play & Weekly Sector Rotation Insights - moha.gov.vn
Why analysts remain bullish on Vir Biotechnology Inc. stock2025 Bull vs Bear & Accurate Intraday Trading Signals - Улправда
Is Vir Biotechnology Inc. stock a buy for dividend growthJuly 2025 Highlights & Weekly Breakout Stock Alerts - Улправда
Momentum Shift: Can Vir Biotechnology Inc. stock beat market expectations this quarterJuly 2025 Highlights & Weekly Stock Breakout Alerts - Улправда
Can Vir Biotechnology Inc. stock sustain revenue growthQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - DonanımHaber
Will Vir Biotechnology Inc. stock outperform value stocks2025 Short Interest & Weekly High Return Stock Opportunities - DonanımHaber
Published on: 2025-12-19 13:20:41 - Улправда
How Vir Biotechnology Inc. stock performs after earnings2025 Trading Volume Trends & Technical Entry and Exit Tips - Улправда
Will Vir Biotechnology Inc. stock recover faster than market2025 Sector Review & Reliable Breakout Forecasts - Улправда
Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Legal Desire Media and Insights
Vir Biotechnology stock gains on Norgine partnership for Hepatitis Delta program - Investing.com Canada
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology | Corporate - EQS News
Norgine Pharmaceuticals Limited - AD HOC NEWS
EQS-News: Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnologyboerse.de - boerse.de
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology - PR Newswire
Vir Biotechnology Licenses CHD Combination Therapy to Norgine for Europe, Australia, New Zealand - marketscreener.com
Vir Biotechnology Secures Licensing Deal with Norgine - TipRanks
Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal - Investing.com Canada
Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) Secures Exclusive Licensing Deal with No - GuruFocus
[8-K] Vir Biotechnology, Inc. Reports Material Event | VIR SEC FilingForm 8-K - Stock Titan
Vir Biotechnology stock rises after licensing hepatitis delta treatment By Investing.com - Investing.com Canada
Vir Biotechnology grants Norgine exclusive commercial license to chronic hepatitis delta treatment candidate - marketscreener.com
Vir Biotechnology Grants Norgine Exclusive Commercial License To Chronic Hepatitis Delta Treatment Candidate - TradingView — Track All Markets
Vir Biotechnology signs agreement with Norgine for hepatitis Delta treatment - Traders Union
Vir Biotechnology grants Norgine exclusive license for hepatitis delta treatment - StreetInsider
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program - Business Wire
Vir Biotechnology Earnings Notes - Trefis
12,916,663 Shares in Vir Biotechnology, Inc. $VIR Bought by ARCH Venture Management LLC - MarketBeat
Vir Biotechnology, Inc. (VIR) Stock Analysis: Uncovering The 159.76% Potential Upside - DirectorsTalk Interviews
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal By Investing.com - Investing.com Canada
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal - Investing.com
After Losing 25% in the Past Year, Vir Biotechnology, Inc. (NASDAQ:VIR) Institutional Owners Must Be Relieved by the Recent Gain - 富途牛牛
Vir Biotechnology (VIR) Gains Positive Outlook Amid Industry Acq - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap UpShould You Buy? - MarketBeat
Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy - simplywall.st
Can Vir Biotechnology (NASDAQ:VIR) Afford To Invest In Growth? - Yahoo Finance
Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool
2.52%
0.07%
자본화:
|
볼륨(24시간):